ProPhase Labs (NSDQ:PRPH) announced today that it is introducing a new saliva-based test for COVID-19, Influenza A, B and more.
Garden City, N.Y.-based ProPhase Labs said in a news release that it filed for FDA emergency use authorization for its two new testing methodologies, which integrate the Spectrum Solutions saliva self-collection system with a new multiplex qPCR platform for simultaneous RNA detection of SARS-CoV-2, COVID-19 viral mutations, Influenza A, B and more.
The SDNA Viral saliva-based testing combination offers pain-free self-collection, 100% in-device viral neutralization, the removal of the need for cold-chain storage of samples and overall consistency and accuracy, ProPhase Labs said.
Spectrum Solutions developed the first saliva-based COVID-19 test to garner FDA EUA in April, working in tandem with Accurate Diagnostics Labs and Rutgers University’s RUCDR.
“We are privileged t…